Clinical trial · Interventional
Impact of Thyroid Hormones on Human Glucose and Energy Metabolism
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The goal of this clinical trial to clarify the impact of changes in thyroid hormone levels on glucose and lipid metabolism. Patients will be included in whom thyroid hormone levels are intentionally changed by treatment. In patients with Graves' disease, thyroid hormone levels will be lowered using medication, while in patients with thyroid cancer, thyroid hormone levels will be raised using medication. Oral glucose tolerance tests will be performed before treatment and at two time points after treatment begins to assess metabolic effects.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Graves Disease | — | UNRESOLVED | — |
| Thyroid Cancer | Malignant Thyroid Gland Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Oral Glucose Tolerance Test | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- OTHER
- label
- Phenotyping Cohort
- description
- Patients with Graves' disease and patients with thyroid carcinoma undergoing standard-of-care thyroid treatment.
- interventionNames
- Other: Oral Glucose Tolerance Test
Primary outcomes (2)
- measure
- Insulin sensitivity
- timeFrame
- Baseline, 2 weeks, 3 months
- description
- Effect of changes in thyroid hormone levels on whole-body insulin sensitivity, assessed from glucose and insulin measurements during the 75 g oral glucose tolerance test.
- measure
- Insulin secretion
- timeFrame
- Baseline, 2 weeks, 3 months
- description
- Effect of changes in thyroid hormone levels on insulin secretion, assessed from glucose and insulin/c-peptide measurements during the 75 g oral glucose tolerance test.
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * patients with initial diagnosis of graves disease OR * patients with initial diagnosis of thyroid carcinoma Exclusion Criteria: * contraindications for oral glucose tolerance test * Diabetes mellitus * Fasting glucose level ≥ 200 mg/dL * Exogenous insulin administration with action at the time of the test * Current disease with activation of stress hormones * Post-aggressive metabolism * Acute infectious disease
References
Publications (0)
Data not yet available